Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology?

Bibliography

• STEIDLER L, HANS W, SCHOTTE L: et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289(5483):1352–1355.
   Google Scholar
• ••Proof of concept for therapeutic use ofGM lactococci.
   Google Scholar
• STEIDLER L, ROBINSON K, CHAMBERLAIN L et al.: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect. Inman. (1998) 66(7):3183–3189.
   PubMed Web of Science ®Google Scholar
• •First demonstration of protein delivery at the mucosa by GM lactococci.
   Google Scholar
• STEIDLER L, WELLS JM, RAEYMAEKERS A, VANDEKERCKHOVE J, FIERS W, REMAUT E: Secretion of biologically active murine interleukin-2 by Lactococcus /actissubsp. lactis. Appl. Environ. Microbiol (1995) 61(4):1627–1629.
   PubMed Web of Science ®Google Scholar
• •First cytokine secreted by GM lactococci.
   Google Scholar
• STEIDLER L, FIERS W, REMAUT E: Expression of human and murine interleukins in Lactococcus lactis. In: NATO-ASI series H98 on 'Current Advances in Genetics, Metabolism and Application of Lactic Acid Bacteria: Bozoglu F, Ray B (Eds), Springer Verlag, Heidelberg (1996):63–79.
   Google Scholar
• SCHOTTE L, STEIDLER L, VANDEKERCKHOVE J, REMAUT E: Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb. 7echnol. (2000) 27(10):761–765.
   Google Scholar
• BENINATI C, OGGIONI MR, BOCCANERA M et al: Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol (2000) 18(10):1060–1064.
   PubMed Web of Science ®Google Scholar
• •Use of GM bacteria for single chain antibody therapy.
   Google Scholar
• KRUGER C, HU Y, PAN Q et al: In situ delivery of passive immunity by lactobacilli producing single- chain antibodies. Nat. Biotechnol (2002) 20(7):702–706.
   PubMed Web of Science ®Google Scholar
• BERMUDEZ-HUMARAN LG, LANGELLA P, CORTES-PEREZ NG et al.: Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Thl cytokine production. Infect. Iminun. (2003) 71(4):1887–1896.
   PubMed Web of Science ®Google Scholar
• SHANAHAN F: Crohn's disease. Lancet (2002) 359(9300):62–69.
   PubMed Web of Science ®Google Scholar
• VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology (1997) 113(2):383–389.
   PubMed Web of Science ®Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119(6):1473–1482.
   Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461–1472.
   Google Scholar
• TILG H, ULMER H, KASER A,WEISS G: Role of IL-10 for induction of anemia during inflammation. I Immunol (2002) 169(4):2204–2209.
   PubMed Web of Science ®Google Scholar
• TILG H, VAN MONTFRANS C, VAN DEN ENDE A et al.: Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 50(2):191–195. Mechanistic insight in failure of systemic IL-10 for Crohn's disease treatment.
   Google Scholar
• COLOMBEL JF, RUTGEERTS P, MALCHOW H et al.: Interleuldn 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49(1):42–46.
   PubMed Web of Science ®Google Scholar
• SCHREIBER S, FEDORAK RN, NIELSEN OH et al: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461–1472.
   Google Scholar
• MASOOD R, ZHANG Y, BOND MW et al.: Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 85(12):3423–3430.
   PubMed Web of Science ®Google Scholar
• STEIDLER L, NEIRYNCK S, HUYGHEBAERT N et al.: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol (2003) 21(7):785–789.
   PubMed Web of Science ®Google Scholar
• ••Biological containment of GM lactococci.
   Google Scholar
• ALPERT C-A, MATER DDG, MULLER M-C, OURIET M-F, DUVAL-IFLAH Y, CORTHIER G: Worst-case scenarios for horizontal gene transfer from Lactococcus lactis carrying heterologous genes to Enterococcus faecalisin the digestive tract of gnotobiotic mice. Environ. Biosafeo Res. (2004) 2:173–180.
   Google Scholar